Drug Discovery & Pharmaceuticals

RSS
Hamamatsu introduces the New FDSS-GX: the highest-performance kinetic plate imager in the FDSS series

Hamamatsu introduces the New FDSS-GX: the highest-performance kinetic plate imager in the FDSS series

SCIEX expands high-throughput screening solutions with Echoâ MS+ system

SCIEX expands high-throughput screening solutions with Echoâ MS+ system

Almirall and Microsoft partner on AI-powered drug discovery in dermatology

Almirall and Microsoft partner on AI-powered drug discovery in dermatology

New molecule is one step closer to becoming a treatment for Phelan-McDermid syndrome

New molecule is one step closer to becoming a treatment for Phelan-McDermid syndrome

Researchers discover non-opioid therapeutic for relieving neuropathic pain

Researchers discover non-opioid therapeutic for relieving neuropathic pain

CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market

CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market

Enterprise Therapeutics closes £26 million ($33.1 million) Series B follow-on financing

Enterprise Therapeutics closes £26 million ($33.1 million) Series B follow-on financing

New DNA-based vaccine can induce strong antibody response against SARS-CoV-2

New DNA-based vaccine can induce strong antibody response against SARS-CoV-2

New study opens unprecedented opportunities for bioengineering vaccine adjuvants

New study opens unprecedented opportunities for bioengineering vaccine adjuvants

CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies

CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies

C-Path's TRxA launches 2024 grants to boost next-gen therapeutics

C-Path's TRxA launches 2024 grants to boost next-gen therapeutics

Moffitt researchers develop novel reagent for efficient synthesis of sulfur-containing drug candidates

Moffitt researchers develop novel reagent for efficient synthesis of sulfur-containing drug candidates

AI scores breakthrough in anemia treatment with novel PHD inhibitor

AI scores breakthrough in anemia treatment with novel PHD inhibitor

Insilico Medicine leverages AI to identify promising new target for breast and gynecological cancers

Insilico Medicine leverages AI to identify promising new target for breast and gynecological cancers

Conscience's open science competition yields hits for new Parkinson's drugs

Conscience's open science competition yields hits for new Parkinson's drugs

New analysis of cancer cells identifies 370 targets for smarter, personalized treatments

New analysis of cancer cells identifies 370 targets for smarter, personalized treatments

New compound effective against bacterial species resistant to multiple classes of existing antibiotics

New compound effective against bacterial species resistant to multiple classes of existing antibiotics

New synthetic antibiotic found to be more effective than established drugs against 'superbugs'

New synthetic antibiotic found to be more effective than established drugs against 'superbugs'

Scripps scientists develop powerful method to find drug targets in live cells

Scripps scientists develop powerful method to find drug targets in live cells

Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors

Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.